To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c (LEAD-3)

This study has been terminated.
(Trial was terminated at week 195 due to an insufficient number of subjects remaining to obtain reasonable statistical power)
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT00294723
First received: February 20, 2006
Last updated: July 9, 2012
Last verified: July 2012
  Purpose

This trial is conducted in North America (the United States of America (USA) and Mexico).

The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects with type 2 diabetes. The trial is a 52-week randomised, double-blind trial period plus a 52-week open-label extension (week 104) followed by an additional 156-week continued open-label extension. The total duration of the treatment period is planned to be 260 weeks (5 years).


Condition Intervention Phase
Diabetes
Diabetes Mellitus, Type 2
Drug: liraglutide
Drug: glimepiride
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Liraglutide Effect and Action in Diabetes (LEAD-3): Effect on Glycemic Control of Liraglutide Versus Glimepiride in Type 2 Diabetes

Resource links provided by NLM:


Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 52 [ Time Frame: week 0, week 52 ] [ Designated as safety issue: No ]
    Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 52 weeks (end of double-blind period)

  • Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 104 [ Time Frame: week 0, week 104 ] [ Designated as safety issue: No ]
    Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 104 weeks (end of 52-week extension)

  • Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 156 [ Time Frame: week 0, week 156 ] [ Designated as safety issue: No ]
    Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 156 weeks


Secondary Outcome Measures:
  • Change in Body Weight at Week 52 [ Time Frame: week 0, week 52 ] [ Designated as safety issue: No ]
    Change in body weight from baseline (week 0) to 52 weeks (end of double-blind period)

  • Change in Body Weight at Week 104 [ Time Frame: week 0, week 104 ] [ Designated as safety issue: No ]
    Change in body weight from baseline (week 0) to 104 weeks (end of 52-week extension)

  • Change in Body Weight at Week 156 [ Time Frame: week 0, week 156 ] [ Designated as safety issue: No ]
    Change in body weight from baseline (week 0) to 156 weeks

  • Change in Fasting Plasma Glucose at Week 52 [ Time Frame: week 0, week 52 ] [ Designated as safety issue: No ]
    Change in fasting plasma glucose (FPG) from baseline (week 0) to 52 weeks (end of double-blind period)

  • Change in Fasting Plasma Glucose at Week 104 [ Time Frame: week 0, week 104 ] [ Designated as safety issue: No ]
    Change in fasting plasma glucose (FPG) from baseline (week 0) to 104 weeks (end of 52-week extension)

  • Change in Fasting Plasma Glucose at Week 156 [ Time Frame: week 0, week 156 ] [ Designated as safety issue: No ]
    Change in fasting plasma glucose (FPG) from baseline (week 0) to 156 weeks

  • Change in Mean Postprandial Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 52 [ Time Frame: week 0, week 52 ] [ Designated as safety issue: No ]
    Change in mean postprandial glucose (PPG) based on self-measured 8-point plasma glucose profiles from baseline (week 0) to 52 weeks (end of double-blind period). The 8 time points for self-measurements of plasma glucose were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min.

  • Change in Mean Postprandial Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 104 [ Time Frame: week 0, week 104 ] [ Designated as safety issue: No ]
    Change in mean postprandial glucose (PPG) based on self-measured 8-point plasma glucose profiles from baseline (week 0) to 104 weeks (end of 52-week extension). The 8 time points for self-measurements of plasma glucose were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min.

  • Change in Mean Postprandial Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 156 [ Time Frame: week 0, week 156 ] [ Designated as safety issue: No ]
    Change in mean postprandial glucose (PPG) based on self-measured 8-point plasma glucose profiles from baseline (week 0) to 156 weeks. The 8 time points for self-measurements of plasma glucose were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min.

  • Change in Prandial Increments of Plasma Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 52 [ Time Frame: week 0, week 52 ] [ Designated as safety issue: No ]
    Change in mean prandial increments of plasma glucose from baseline (week 0) to 52 weeks (end of double-blind period). The 8 time points for self-measured 8-point plasma glucose profiles were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between post- and pre-meal values (for breakfast, lunch and dinner) divided by three.

  • Change in Prandial Increments of Plasma Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 104 [ Time Frame: week 0, week 104 ] [ Designated as safety issue: No ]
    Change in mean prandial increments of plasma glucose from baseline (week 0) to 104 weeks (end of 52-week extension). The 8 time points for self-measured 8-point plasma glucose profiles were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between post- and pre-meal values (for breakfast, lunch and dinner) divided by three.

  • Change in Prandial Increments of Plasma Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 156 [ Time Frame: week 0, week 156 ] [ Designated as safety issue: No ]
    Change in mean prandial increments (incr.) of plasma glucose from baseline (week 0) to 156 weeks. The 8 time points for self-measured 8-point plasma glucose profiles were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between post- and pre-meal values (for breakfast, lunch and dinner) divided by three.

  • Hypoglycaemic Episodes [ Time Frame: weeks 0-104 ] [ Designated as safety issue: Yes ]
    Total number of hypoglycaemic episodes occuring from baseline (week 0) to 104 weeks (end of the 52-week extension). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 56 mg/dL. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 56 mg/dL.

  • Hypoglycaemic Episodes [ Time Frame: weeks 104-195 ] [ Designated as safety issue: Yes ]
    Total number of hypoglycaemic episodes occuring from week 104 to end of trial (week 195). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 56 mg/dL. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 56 mg/dL.


Enrollment: 746
Study Start Date: February 2006
Study Completion Date: March 2010
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lira 1.8
Liraglutide 1.8 mg once daily + glimepiride placebo 8 mg once daily, weeks 0-52 (double-blinded period) and open-label liraglutide 1.8 mg once daily in the extension periods (weeks 52-195).
Drug: liraglutide
1.8 mg for s.c. (under the skin) injection
Drug: placebo
Glimepiride placebo, 8mg capsule
Experimental: Lira 1.2
Liraglutide 1.2 mg once daily + glimepiride placebo 8 mg once daily, weeks 0-52 (double-blinded period) and open-label liraglutide 1.2 mg once daily in the extension periods (weeks 52-195).
Drug: liraglutide
1.2 mg for s.c. (under the skin) injection
Drug: placebo
Glimepiride placebo, 8mg capsule
Active Comparator: Glimepiride - 1
Glimepiride 8 mg once daily + liraglutide placebo 200 mcl, weeks 0-52 (double-blinded period) and open-label glimepiride 8 mg once daily in the extension periods (weeks 52-195).
Drug: glimepiride
8 mg capsule
Drug: placebo
Liraglutide placebo, 200 mcl
Active Comparator: Glimepiride - 2
Glimepiride 8 mg once daily + liraglutide placebo 300 mcl, weeks 0-52 (double-blinded period) and open-label glimepiride 8 mg once daily in the extension periods (weeks 52-195).
Drug: glimepiride
8 mg capsule
Drug: placebo
Liraglutide placebo, 300 mcl

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 diabetes
  • TTreatment with diet/exercise or with not more than half maximal dose of oral anti-diabetic drugs alone for at least 2 months
  • Diet/exercise treated subjects with HbA1c between 7.0% and 11%, inclusive
  • OAD (oral anti-diabetic drug) treated subjects with HbA1c between 7.0% and 10%, inclusive
  • Body Mass Index (BMI) less than or equal to 45 kg/m^2

Exclusion Criteria:

  • Treatment with insulin for the last 3 months, except short-term treatment for intercurrent illness
  • Treatment with any drug that could interfere with the glucose level (besides use of a single anti-diabetic compound)
  • Any serious medical condition
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00294723

  Hide Study Locations
Locations
United States, California
Novo Nordisk Clinical Trial Call Center
Concord, California, United States, 94520
Novo Nordisk Clinical Trial Call Center
Escondido, California, United States, 92026
Novo Nordisk Clinical Trial Call Center
Inglewood, California, United States, 90301
Novo Nordisk Clinical Trial Call Center
Mission Viejo, California, United States, 92691
Novo Nordisk Clinical Trial Call Center
Orange, California, United States, 92869
Novo Nordisk Clinical Trial Call Center
Santa Barbara, California, United States, 93105
Novo Nordisk Clinical Trial Call Center
Spring Valley, California, United States, 91978
Novo Nordisk Clinical Trial Call Center
Vista, California, United States, 92084
Novo Nordisk Clinical Trial Call Center
Walnut Creek, California, United States, 94598
United States, Florida
Novo Nordisk Clinical Trial Call Center
Daytona Beach, Florida, United States, 32117
Novo Nordisk Clinical Trial Call Center
Jacksonville, Florida, United States, 32216
Novo Nordisk Clinical Trial Call Center
Jacksonville, Florida, United States, 32205
Novo Nordisk Clinical Trial Call Center
Longwood, Florida, United States, 32779
Novo Nordisk Clinical Trial Call Center
Ocala, Florida, United States, 34471
Novo Nordisk Clinical Trial Call Center
St. Cloud, Florida, United States, 34769
United States, Georgia
Novo Nordisk Clinical Trial Call Center
Athens, Georgia, United States, 30606
Novo Nordisk Clinical Trial Call Center
Atlanta, Georgia, United States, 30339
Novo Nordisk Clinical Trial Call Center
Atlanta, Georgia, United States, 30032
Novo Nordisk Clinical Trial Call Center
Atlanta, Georgia, United States, 30309
Novo Nordisk Clinical Trial Call Center
Atlanta, Georgia, United States, 30034
Novo Nordisk Clinical Trial Call Center
Blue Ridge, Georgia, United States, 30513
Novo Nordisk Clinical Trial Call Center
Columbus, Georgia, United States, 31904
Novo Nordisk Clinical Trial Call Center
Powder Springs, Georgia, United States, 30127
Novo Nordisk Clinical Trial Call Center
Tucker, Georgia, United States, 30084
United States, Hawaii
Novo Nordisk Clinical Trial Call Center
Honolulu, Hawaii, United States, 96813
United States, Illinois
Novo Nordisk Clinical Trial Call Center
Chicago, Illinois, United States, 60607
United States, Indiana
Novo Nordisk Clinical Trial Call Center
Indianapolis, Indiana, United States, 46202
United States, Iowa
Novo Nordisk Clinical Trial Call Center
Des Moines, Iowa, United States, 50314
United States, Kansas
Novo Nordisk Clinical Trial Call Center
Shawnee Mission, Kansas, United States, 66204
Novo Nordisk Clinical Trial Call Center
Topeka, Kansas, United States, 66606
United States, Kentucky
Novo Nordisk Clinical Trial Call Center
Lexington, Kentucky, United States, 40503
Novo Nordisk Clinical Trial Call Center
Lexington, Kentucky, United States, 40504-2681
United States, Louisiana
Novo Nordisk Clinical Trial Call Center
New Orleans, Louisiana, United States, 70121
United States, Maryland
Novo Nordisk Clinical Trial Call Center
Baltimore, Maryland, United States, 21218
Novo Nordisk Clinical Trial Call Center
Hyattsville, Maryland, United States, 20782
United States, Minnesota
Novo Nordisk Clinical Trial Call Center
Minneapolis, Minnesota, United States, 55407
Novo Nordisk Clinical Trial Call Center
St. Paul, Minnesota, United States, 55108
United States, Mississippi
Novo Nordisk Clinical Trial Call Center
Jackson, Mississippi, United States, 39216
Novo Nordisk Clinical Trial Call Center
Tupelo, Mississippi, United States, 38801
United States, Missouri
Novo Nordisk Clinical Trial Call Center
Chesterfield, Missouri, United States, 63017
Novo Nordisk Clinical Trial Call Center
St. Louis, Missouri, United States, 63104
Novo Nordisk Clinical Trial Call Center
St. Louis, Missouri, United States, 63110
Novo Nordisk Clinical Trial Call Center
St. Peters, Missouri, United States, 63376
United States, Montana
Novo Nordisk Clinical Trial Call Center
Butte, Montana, United States, 59701
United States, Nebraska
Novo Nordisk Clinical Trial Call Center
Omaha, Nebraska, United States, 68114
United States, Nevada
Novo Nordisk Clinical Trial Call Center
Las Vegas, Nevada, United States, 89103
Novo Nordisk Clinical Trial Call Center
Reno, Nevada, United States, 89502
United States, New Jersey
Novo Nordisk Clinical Trial Call Center
Berlin, New Jersey, United States, 08009
Novo Nordisk Clinical Trial Call Center
Lawrenceville, New Jersey, United States, 08648
Novo Nordisk Clinical Trial Call Center
Princeton, New Jersey, United States, 08540
United States, New York
Novo Nordisk Clinical Trial Call Center
Albany, New York, United States, 12206
Novo Nordisk Clinical Trial Call Center
New York, New York, United States, 10023
Novo Nordisk Clinical Trial Call Center
Northport, New York, United States, 11768
Novo Nordisk Clinical Trial Call Center
Staten Island, New York, United States, 10301
Novo Nordisk Clinical Trial Call Center
Syracuse, New York, United States, 13210
Novo Nordisk Clinical Trial Call Center
West Seneca, New York, United States, 14224
United States, North Carolina
Novo Nordisk Clinical Trial Call Center
Asheville, North Carolina, United States, 28801
Novo Nordisk Clinical Trial Call Center
Charlotte, North Carolina, United States, 28277
Novo Nordisk Clinical Trial Call Center
Durham, North Carolina, United States, 27710
Novo Nordisk Clinical Trial Call Center
Greensboro, North Carolina, United States, 27408
United States, Ohio
Novo Nordisk Clinical Trial Call Center
Cleveland, Ohio, United States, 44195
Novo Nordisk Clinical Trial Call Center
Dayton, Ohio, United States, 45439
Novo Nordisk Clinical Trial Call Center
Mentor, Ohio, United States, 44060
United States, Oklahoma
Novo Nordisk Clinical Trial Call Center
Oklahoma City, Oklahoma, United States, 73103
Novo Nordisk Clinical Trial Call Center
Tulsa, Oklahoma, United States, 74105
Novo Nordisk Clinical Trial Call Center
Tulsa, Oklahoma, United States, 74104
United States, Oregon
Novo Nordisk Clinical Trial Call Center
Bend, Oregon, United States, 97710
Novo Nordisk Clinical Trial Call Center
Eugene, Oregon, United States, 97401
Novo Nordisk Clinical Trial Call Center
Medford, Oregon, United States, 97504
United States, Pennsylvania
Novo Nordisk Clinical Trial Call Center
Lancaster, Pennsylvania, United States, 17601
Novo Nordisk Clinical Trial Call Center
Norristown, Pennsylvania, United States, 19401
Novo Nordisk Clinical Trial Call Center
Philadelphia, Pennsylvania, United States, 19107
United States, Rhode Island
Novo Nordisk Clinical Trial Call Center
East Providence, Rhode Island, United States, 02914
United States, South Carolina
Novo Nordisk Clinical Trial Call Center
Greer, South Carolina, United States, 29651
Novo Nordisk Clinical Trial Call Center
Spartanburg, South Carolina, United States, 29303
United States, Tennessee
Novo Nordisk Clinical Trial Call Center
Chattanooga, Tennessee, United States, 37411
United States, Texas
Novo Nordisk Clinical Trial Call Center
Arlington, Texas, United States, 76014
Novo Nordisk Clinical Trial Call Center
Corpus Christi, Texas, United States, 78412
Novo Nordisk Clinical Trial Call Center
Dallas, Texas, United States, 75224
Novo Nordisk Clinical Trial Call Center
Dallas, Texas, United States, 75208
Novo Nordisk Clinical Trial Call Center
Dallas, Texas, United States, 75246
Novo Nordisk Clinical Trial Call Center
Dallas, Texas, United States, 75231
Novo Nordisk Clinical Trial Call Center
Dallas, Texas, United States, 75230
Novo Nordisk Clinical Trial Call Center
Houston, Texas, United States, 77024
Novo Nordisk Clinical Trial Call Center
Houston, Texas, United States, 77025
Novo Nordisk Clinical Trial Call Center
Houston, Texas, United States, 77030
Novo Nordisk Clinical Trial Call Center
Houston, Texas, United States, 77074
Novo Nordisk Clinical Trial Call Center
Midland, Texas, United States, 79707
Novo Nordisk Clinical Trial Call Center
San Antonio, Texas, United States, 78229
United States, Utah
Novo Nordisk Clinical Trial Call Center
Salt Lake City, Utah, United States, 84132
United States, Virginia
Novo Nordisk Clinical Trial Call Center
Richmond, Virginia, United States, 23249
United States, Washington
Novo Nordisk Clinical Trial Call Center
Olympia, Washington, United States, 98502
Novo Nordisk Clinical Trial Call Center
Renton, Washington, United States, 98057
Novo Nordisk Clinical Trial Call Center
Spokane, Washington, United States, 99207
Novo Nordisk Clinical Trial Call Center
Tacoma, Washington, United States, 98405
Mexico
Ciudad de México, D.F., Mexico, 06100
Ciudad de México, D.F., Mexico, 14050
Cuernavaca, Mor., Mexico, 62250
Guadalajara, Mexico, 44600
Guadalajara, Mexico, 44650
Hermosillo, Son., Mexico, 83000
Mexico D.F., Mexico, 06700
Mexico, D.F., Mexico, 01120
Monterrey, Mexico, 64460
Monterrey, N.L., Mexico, 64000
Monterrey, NL, Mexico, 66260
Santiago de Querétaro, Qro., Mexico, 76178
Tampico, Mexico, 80109
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Study Director: Paula Hale, MD Novo Nordisk A/S
  More Information

Additional Information:
No publications provided by Novo Nordisk A/S

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT00294723     History of Changes
Obsolete Identifiers: NCT00853359
Other Study ID Numbers: NN2211-1573
Study First Received: February 20, 2006
Results First Received: February 23, 2010
Last Updated: July 9, 2012
Health Authority: Mexico: Federal Commission for Protection Against Health Risks
United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Glimepiride
Glucagon-Like Peptide 1
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions
Immunosuppressive Agents
Immunologic Factors
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists

ClinicalTrials.gov processed this record on April 17, 2014